Barclays PLC Argenx Se Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Argenx Se stock. As of the latest transaction made, Barclays PLC holds 305 shares of ARGX stock, worth $172,090. This represents 0.0% of its overall portfolio holdings.

Number of Shares

305

Previous 27,000 98.87%

Holding current value

$172,090

Previous $11.6 Million 98.57%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$434.22 - $551.9 $132,437 - $168,329	305 New	305 $166,000
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $4.35 Million - $5.03 Million	-12,180 Reduced 29.4%	29,250 $11.5 Million
Q4 2023 Feb 15, 2024	BUY	$338.91 - $506.01 $839,818 - $1.25 Million	2,478 Added 6.36%	41,430 $15.8 Million
Q3 2023 Nov 07, 2023	BUY	$369.35 - $548.43 $11.7 Million - $17.3 Million	31,596 Added 429.53%	38,952 $19.1 Million
Q2 2023 Aug 03, 2023	SELL	$360.14 - $422.58 $11.5 Million - $13.5 Million	-32,007 Reduced 81.31%	7,356 $2.87 Million
Q1 2023 May 04, 2023	BUY	$334.23 - $403.65 $13.1 Million - $15.8 Million	39,266 Added 40480.41%	39,363 $14.7 Million
Q3 2022 Nov 03, 2022	SELL	$343.2 - $395.75 $201,115 - $231,909	-586 Reduced 85.8%	97 $34,000
Q2 2022 Aug 12, 2022	BUY	$269.58 - $378.88 $157,973 - $222,023	586 Added 604.12%	683 $259,000
Q4 2021 Feb 14, 2022	SELL	$272.01 - $353.03 $1.3 Million - $1.69 Million	-4,773 Reduced 98.01%	97 $34,000
Q3 2021 Nov 09, 2021	BUY	$295.0 - $350.58 $194,110 - $230,681	658 Added 15.62%	4,870 $1.47 Million
Q2 2021 Aug 13, 2021	SELL	$257.11 - $319.92 $115,442 - $143,644	-449 Reduced 9.63%	4,212 $1.27 Million
Q1 2021 May 13, 2021	BUY	$268.3 - $380.31 $1.24 Million - $1.75 Million	4,611 Added 9222.0%	4,661 $1.28 Million
Q3 2020 Nov 12, 2020	BUY	$215.51 - $272.51 $10,775 - $13,625	50 New	50 $13,000
Q2 2020 Aug 12, 2020	SELL	$127.44 - $232.72 $12,744 - $23,272	-100 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$108.83 - $165.23 $100,014 - $151,846	-919 Reduced 90.19%	100 $13,000
Q4 2019 Feb 10, 2020	SELL	$106.59 - $164.21 $2.2 Million - $3.38 Million	-20,611 Reduced 95.29%	1,019 $163,000
Q3 2019 Nov 14, 2019	BUY	$113.31 - $150.51 $1.6 Million - $2.13 Million	14,130 Added 188.4%	21,630 $2.47 Million
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $2.77 Million - $3.41 Million	-24,084 Reduced 76.25%	7,500 $1.06 Million
Q1 2019 May 15, 2019	BUY	$98.85 - $134.59 $84,912 - $115,612	859 Added 2.8%	31,584 $3.94 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $764,762 - $1.32 Million	-11,985 Reduced 28.06%	30,725 $2.95 Million
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $453,000 - $579,780	6,000 Added 16.34%	42,710 $3.24 Million
Q1 2018 May 15, 2018	BUY	$56.95 - $85.19 $2.09 Million - $3.13 Million	36,710 New	36,710 $2.95 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account